RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: Ar I guess someone else put you on ignore.
Clearly beenther if I bought MDG based on book value and I have been in it for 4 years, I would be far better of than at the break even point at .55
MDG are not the inventors of this technology, they have brought it to a produceable level however.
I am not certain they own a VLP patent, but I think the production process patent using the tobacco like plant is theirs.
Others are already producing VLP,s using other methods and you can be sure it won't be long before some one else will do it as well as MDG, and by the way patents only last about 17 years or so and this one has already been around for a while.
I doubt the patent rights could be sold for 40 million, its the technology that is not public that gives MDG the edge, the people and special purpose equipment they have developed.
Its not quite like a drug patent.
I believe the money that MDG makes will be primarily on setting up and operating facilities like the one in NC and collecting royalties on the vaccines those facilities manufacture on a dose by dose basis.
Its more about the manufacturing or production technology than the formula of the product as far as I can tell. The formula is defined by the virus itself which is different for different viruses.
So the value of the patents are not likely what you expect if you are basing them on drug patents.
What about the rest of it, do you think that the share price is below the book value then?